Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma
Graphical abstract
Section snippets
Acknowledgements
We would like to thank Dr. James Stone and Dr. Dongfeng Pan for access to lab facilities. We also thank Dr. Bijoy Kundu, Dr. Yi Zhang and Dr. Mahendra Chordia for helpful discussions. Research reported in this publication was partially supported by the National Cancer Institute (CCSG P30 CA44579 and R01CA135358). The content is solely the responsibility of the authors, and does not necessarily represent the official views of the National Institutes of Health.
References (20)
PARP inhibitors in ovarian cancer
Ann Oncol
(2016)- et al.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
Ann Oncol
(2012) - et al.
Poly (adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region
Hum Pathol
(2005) - et al.
PARPi-FL-a fluorescent PARP1 inhibitor for glioblastoma imaging
Neoplasia
(2014) - et al.
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma
Biomaterials
(2011) - et al.
Radiopharmaceutical chemistry for positron emission tomography
Adv Drug Deliv Rev
(2010) - et al.
Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo
Nucl Med Biol
(2016) - et al.
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
Biochem J
(1999) - et al.
DNA repair pathways as targets for cancer therapy
Nat Rev Cancer
(2008) - et al.
Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types
Genes Cancer
(2010)
There are more references available in the full text version of this article.
Cited by (0)
© 2017 Elsevier Ltd. All rights reserved.